
- Fresenius SE has increased its full-year forecast for organic revenue growth to a range of 5% to 7%, up from the previous estimate of 4% to 6%.
- The company expects its Earnings Before Interest and Taxes (Ebit) to grow between 3% to 7%.
- For the second quarter, Fresenius reported Ebit before special items of €654 million, slightly surpassing the estimate of €637.9 million.
- Kabi, a division of Fresenius, recorded Ebit before special items of €346 million, just below the estimate of €348.6 million.
- The Helios division reported Ebit before special items of €337 million, beating the estimated €334.5 million.
- Total sales for the company were €5.57 billion.
- Sales for Kabi amounted to €2.11 billion, while Helios sales reached €3.37 billion.
- Net income excluding special items was €412 million, which was below the estimated €452.6 million.
- Fresenius notes that its guidance takes into account current factors and known uncertainties, including potential impacts from tariffs.
“`
Fresenius & KGaA on Smartkarma
Analysts on Smartkarma, such as Baptista Research, have been closely monitoring Fresenius SE & Co. The research report titled “Fresenius SE & Co: Will Aggressive Pipeline Expansion Be the Secret to Long-Term Dominance?” showcases a positive outlook on the company. Fresenius showed strong financial performance in the first quarter of 2025, with significant growth in earnings per share (EPS) by 12% year-over-year. This growth reflects the company’s operational efficiency and strategic market positioning, as highlighted in the research report by Baptista Research.
Analysts from Baptista Research emphasized the promising momentum across Fresenius’ business segments, leading to confidence in the company’s full-year guidance. The report points towards Fresenius’ disciplined capital deployment and robust strategic initiatives as key drivers of its success. With a bullish sentiment, the analysts are optimistic about Fresenius’ long-term dominance in the market, attributing its potential to the aggressive pipeline expansion outlined in the insightful research available on Smartkarma.
A look at Fresenius & KGaA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts utilizing the Smartkarma Smart Scores have provided insights into the long-term outlook for Fresenius SE & Co KGaA. With strong scores in Value and Dividend at 4, and Momentum at 4 as well, the company is positioned favorably in terms of investment potential. While Growth and Resilience scores are slightly lower at 3, the overall outlook remains positive for the global healthcare group.
Fresenius SE & Co KGaA, a company specializing in healthcare products and services such as dialysis, infusion, and diagnostics equipment, has shown resilience with a score of 3 in this aspect. Investors looking for stable dividends and value in their investments may find Fresenius an attractive option based on its solid scores in these areas. With a diverse range of products catering to healthcare needs, Fresenius presents itself as a strong contender for long-term investment prospects.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars